Research and Markets: USA Pharmaceutical Pricing & Reimbursement Concise Guide

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "IMS Pricing & Reimbursement Concise Guide: USA" report to their offering.

USA Pharmaceutical Pricing & Reimbursement Concise Guide

The P&R Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Key Topics Covered:

Healthcare System

  • Facts & Figures
  • Market Indicators
  • Provision & Funding


  • Prescription Drugs
  • Private Plans
  • Medicare Part B
  • Medicare Part D
  • Medicaid
  • Other Federal Programmes
  • Generic Drugs
  • Hospital Drugs
  • Otc Drugs


  • Admission to Reimbursement
  • Private Plans
  • Medicare Part B
  • Medicare Part D
  • Medicaid
  • Other Federal Programmes
  • Reimbursement Categories
  • Reimbursement Prices
  • Hospital Reimbursement
  • Formularies
  • Funding
  • Changes in Reimbursement Status
  • Changes in Reimbursement Prices


  • Pharmacoeconomic Requirements

Price Build Up

  • Wholesalers
  • Retail Pharmacies
  • Dispensing Doctors
  • Sales Tax

Cost Containment

  • Industry Paybacks
  • Promotional Costs
  • Patient Co-Payments
  • Private Plans
  • Medicare Part D
  • Medicaid
  • Prescribing Controls
  • Generics
  • Biosimilars
  • Rx-To-Otc Switches
  • Parallel Trade

Future Developments

  • Outlook

Names & Addresses

For more information visit

Source: IMS Health


Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical



Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.